|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:LLGL2-AP2B1 (FusionGDB2 ID:45444) |
Fusion Gene Summary for LLGL2-AP2B1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: LLGL2-AP2B1 | Fusion gene ID: 45444 | Hgene | Tgene | Gene symbol | LLGL2 | AP2B1 | Gene ID | 3993 | 163 |
Gene name | LLGL scribble cell polarity complex component 2 | adaptor related protein complex 2 subunit beta 1 | |
Synonyms | HGL|Hugl-2|LGL2 | ADTB2|AP105B|AP2-BETA|CLAPB1 | |
Cytomap | 17q25.1 | 17q12 | |
Type of gene | protein-coding | protein-coding | |
Description | LLGL scribble cell polarity complex component 2LLGL2, scribble cell polarity complex componenthuman giant larvae homologlethal giant larvae homolog 2, scribble cell polarity complex componentlethal(2) giant larvae protein homolog 2 | AP-2 complex subunit betaadapter-related protein complex 2 beta subunitadapter-related protein complex 2 subunit betaadaptin, beta 2 (beta)adaptor protein complex AP-2 subunit betaadaptor related protein complex 2 beta 1 subunitadaptor-related prote | |
Modification date | 20200320 | 20200327 | |
UniProtAcc | . | P63010 | |
Ensembl transtripts involved in fusion gene | ENST00000167462, ENST00000375227, ENST00000392550, ENST00000578363, ENST00000577200, | ENST00000262325, ENST00000592545, ENST00000538556, ENST00000312678, ENST00000589344, ENST00000537622, ENST00000545922, | |
Fusion gene scores | * DoF score | 17 X 14 X 10=2380 | 14 X 18 X 9=2268 |
# samples | 20 | 19 | |
** MAII score | log2(20/2380*10)=-3.57288966842058 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(19/2268*10)=-3.57734931661128 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: LLGL2 [Title/Abstract] AND AP2B1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | LLGL2(73569712)-AP2B1(34036243), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. | LLGL2-AP2B1 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. LLGL2-AP2B1 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | LLGL2 | GO:0032878 | regulation of establishment or maintenance of cell polarity | 12725730 |
Tgene | AP2B1 | GO:0072583 | clathrin-dependent endocytosis | 23676497 |
Fusion gene breakpoints across LLGL2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across AP2B1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | BLCA | TCGA-FD-A6TH-01A | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
ChimerDB4 | BLCA | TCGA-FD-A6TH-01A | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Top |
Fusion Gene ORF analysis for LLGL2-AP2B1 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Frame-shift | ENST00000167462 | ENST00000262325 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000167462 | ENST00000592545 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000167462 | ENST00000538556 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000167462 | ENST00000312678 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000167462 | ENST00000589344 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000167462 | ENST00000537622 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
5CDS-3UTR | ENST00000167462 | ENST00000545922 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000375227 | ENST00000262325 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000375227 | ENST00000592545 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000375227 | ENST00000538556 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000375227 | ENST00000312678 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000375227 | ENST00000589344 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000375227 | ENST00000537622 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3UTR | ENST00000375227 | ENST00000545922 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000392550 | ENST00000262325 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000392550 | ENST00000592545 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000392550 | ENST00000538556 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000392550 | ENST00000312678 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000392550 | ENST00000589344 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000392550 | ENST00000537622 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
5CDS-3UTR | ENST00000392550 | ENST00000545922 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000578363 | ENST00000262325 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000578363 | ENST00000592545 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000578363 | ENST00000538556 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000578363 | ENST00000312678 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000578363 | ENST00000589344 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3CDS | ENST00000578363 | ENST00000537622 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
intron-3UTR | ENST00000578363 | ENST00000545922 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000577200 | ENST00000262325 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000577200 | ENST00000592545 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000577200 | ENST00000538556 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000577200 | ENST00000312678 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000577200 | ENST00000589344 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
Frame-shift | ENST00000577200 | ENST00000537622 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
5CDS-3UTR | ENST00000577200 | ENST00000545922 | LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036243 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for LLGL2-AP2B1 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036242 | + | 3.97E-05 | 0.9999603 |
LLGL2 | chr17 | 73569712 | + | AP2B1 | chr17 | 34036242 | + | 3.97E-05 | 0.9999603 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for LLGL2-AP2B1 |
Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | AP2B1 |
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Component of the adaptor protein complex 2 (AP-2). Adaptor protein complexes function in protein transport via transport vesicles in different membrane traffic pathways. Adaptor protein complexes are vesicle coat components and appear to be involved in cargo selection and vesicle formation. AP-2 is involved in clathrin-dependent endocytosis in which cargo proteins are incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) which are destined for fusion with the early endosome. The clathrin lattice serves as a mechanical scaffold but is itself unable to bind directly to membrane components. Clathrin-associated adaptor protein (AP) complexes which can bind directly to both the clathrin lattice and to the lipid and protein components of membranes are considered to be the major clathrin adaptors contributing the CCV formation. AP-2 also serves as a cargo receptor to selectively sort the membrane proteins involved in receptor-mediated endocytosis. AP-2 seems to play a role in the recycling of synaptic vesicle membranes from the presynaptic surface. AP-2 recognizes Y-X-X-[FILMV] (Y-X-X-Phi) and [ED]-X-X-X-L-[LI] endocytosis signal motifs within the cytosolic tails of transmembrane cargo molecules. AP-2 may also play a role in maintaining normal post-endocytic trafficking through the ARF6-regulated, non-clathrin pathway. During long-term potentiation in hippocampal neurons, AP-2 is responsible for the endocytosis of ADAM10 (PubMed:23676497). The AP-2 beta subunit acts via its C-terminal appendage domain as a scaffolding platform for endocytic accessory proteins; at least some clathrin-associated sorting proteins (CLASPs) are recognized by their [DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif. The AP-2 beta subunit binds to clathrin heavy chain, promoting clathrin lattice assembly; clathrin displaces at least some CLASPs from AP2B1 which probably then can be positioned for further coat assembly. {ECO:0000269|PubMed:14745134, ECO:0000269|PubMed:14985334, ECO:0000269|PubMed:15473838, ECO:0000269|PubMed:19033387, ECO:0000269|PubMed:23676497}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for LLGL2-AP2B1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for LLGL2-AP2B1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for LLGL2-AP2B1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for LLGL2-AP2B1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | LLGL2 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
Hgene | LLGL2 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
Hgene | LLGL2 | C0678222 | Breast Carcinoma | 1 | CTD_human |
Hgene | LLGL2 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
Hgene | LLGL2 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
Hgene | LLGL2 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
Tgene | AP2B1 | C0086132 | Depressive Symptoms | 1 | PSYGENET |